Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients

Brepocitinib is a tyrosine kinase 2 and Janus kinase 1 inhibitor in development for treatment of inflammatory autoimmune diseases. This analysis aimed to add to the pharmacokinetic knowledge of the medication, through development of a population pharmacokinetic model and identification of factors th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Jim H., Qiu, Ruolun, Banfield, Christopher, Dowty, Martin E., Nicholas, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087980/
https://www.ncbi.nlm.nih.gov/pubmed/36045513
http://dx.doi.org/10.1002/cpdd.1163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087980/
https://www.ncbi.nlm.nih.gov/pubmed/36045513
http://dx.doi.org/10.1002/cpdd.1163

Ejemplares similares